UNSPSC 51151904: Methocarbamol

This classification denotes a muscle relaxant with the molecular formula C11H15NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 125OD7737X, chemically known as 1,2-propanediol, 3-(o-methoxyphenoxy)-, 1-carbamate but generally known as methocarbamol, which bears US NIH Compound Identifier 4107. European Medicines Agency schedules Methocarbamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08852MIG.

UNSPSC 51151904 Methocarbamol, a Commodity code, nominally addresses a specific muscle relaxant pharmaceutical product; however, recent state and local solicitations tagged under this code show no procurement activity for methocarbamol itself. Instead, the opportunities reflect pharmaceutical and health-system procurement more broadly, including naloxone, drug deactivation systems, and direct-to-manufacturer prescription programs. The code shows activity from county health departments and state health and human services agencies seeking pharmaceutical products and services to support community health and pharmacy benefit management. Issuing bodies include Seminole County, Florida's community health division and the Texas Health and Human Services Commission. The scope of actual purchasing under this code tag spans emergency-response pharmaceuticals (naloxone), drug-disposal infrastructure (safe drug deactivation systems), and strategic pharmacy benefit contracting aimed at reducing procurement costs and improving fulfillment efficiency through direct manufacturer relationships.

Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building and fixed-fee pricing with a two-year term and one-year renewal option. The Texas Health and Human Services Commission issued an RFI (HHS0017013) posted April 3, 2026, to gather vendor capability information on direct-to-manufacturer prescription programs designed to bypass traditional pharmacy benefit managers and group purchasing organizations, seeking vendors with experience in direct contracting for self-insured employers and government health plans over the prior two years. The code shows limited recent activity concentrated in the Southeast and South, with no explicit set-aside or disadvantaged-enterprise designations in the two recorded opportunities, though the Seminole County procurement carries potential FEMA funding and associated federal compliance requirements.